Bavituximab

Bavituximab
Monoclonal antibody
TypeWhole antibody
SourceChimeric (mouse/human)
Targetphosphatidylserine
Clinical data
Routes of
administration		infusion
ATC code
  • none
Pharmacokinetic data
Elimination half-life30 hrs
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6446H9946N1702O2042S42
Molar mass145304.87 g·mol−1
  (verify)

Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies,[1][2] and when cells are infected with hepatitis C.[3] The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans.[2]

  1. ^ Cite error: The named reference Adis was invoked but never defined (see the help page).
  2. ^ a b Mahoney KM, Rennert PD, Freeman GJ (August 2015). "Combination cancer immunotherapy and new immunomodulatory targets". Nature Reviews. Drug Discovery. 14 (8): 561–584. doi:10.1038/nrd4591. PMID 26228759. S2CID 2220735.
  3. ^ Cite error: The named reference 2011HepRev was invoked but never defined (see the help page).
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.